These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19076265)

  • 1. Medial septal area vasopressin receptor subtypes in the regulation of urine and sodium excretion in rats.
    Camargo GM; Camargo LA; Saad WA
    J Neuroendocrinol; 2009 Feb; 21(2):151-4. PubMed ID: 19076265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin and angiotensin receptors of the medial septal area in the control of mean arterial pressure induced by vasopressin.
    Pavan de Arruda Camargo GM; Abrão Saad W; de Arruda Camargo LA
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):133-8. PubMed ID: 18957383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin and angiotensin receptors of the medial septal area of the brain in the control of thirst and salt appetite induced by vasopressin in water-deprived and sodium-depleted rats.
    Maria Pavan de Arruda Camargo G; Antônio de Arruda Camargo L; Saad WA
    Pharmacol Biochem Behav; 2007 Oct; 87(4):393-9. PubMed ID: 17573101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medial septal area ANG II receptor subtypes in the regulation of urine and sodium excretion induced by vasopressin.
    Pavan de Arruda Camargo GM; de Arruda Camargo LA; Abrão Saad W
    J Renin Angiotensin Aldosterone Syst; 2011 Mar; 12(1):23-8. PubMed ID: 20663845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of angiotensin and vasopressin V(1) receptors on water and sodium intake induced by injection of vasopressin into lateral septal area.
    Mima EG; Andrade RR; Camargo LA; Saad WA
    Regul Pept; 2004 May; 118(3):159-64. PubMed ID: 15003832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between paraventricular nucleus and medial septal area on the renal effects induced by adrenaline.
    de Arruda Camargo LA; Saad WA; de Souza Villa P
    Auton Neurosci; 2004 Apr; 111(2):135-9. PubMed ID: 15182743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
    J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced effect of neuropeptide Y on food intake caused by blockade of the V(1A) vasopressin receptor.
    Aoyagi T; Kusakawa S; Sanbe A; Hiroyama M; Fujiwara Y; Yamauchi J; Tanoue A
    Eur J Pharmacol; 2009 Nov; 622(1-3):32-6. PubMed ID: 19766110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
    Gunnet JW; Matthews JM; Maryanoff BE; de Garavilla L; Andrade-Gordon P; Damiano B; Hageman W; Look R; Stahle P; Streeter AJ; Wines PG; Demarest KT
    Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):320-6. PubMed ID: 16620295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.
    Tahara A; Tsukada J; Tomura Y; Suzuki T; Yatsu T; Shibasaki M
    Vascul Pharmacol; 2007 Jun; 46(6):463-9. PubMed ID: 17395547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
    Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
    Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between arginine vasopressin and angiotensin II receptors in the central regulation of sodium balance.
    Saad WA; Camargo LA; Antunes-Rodrigues J; Saad WA; Guarda IF; Guarda RS
    Regul Pept; 2005 Dec; 132(1-3):53-8. PubMed ID: 16198010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pressor effects of noradrenaline injected into the lateral septal area of unanesthetized rats.
    Scopinho AA; Resstel LB; Antunes-Rodrigues J; Corrêa FM
    Brain Res; 2006 Nov; 1122(1):126-34. PubMed ID: 17011526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin modulates lateral septal network activity via two distinct electrophysiological mechanisms.
    Allaman-Exertier G; Reymond-Marron I; Tribollet E; Raggenbass M
    Eur J Neurosci; 2007 Nov; 26(9):2633-42. PubMed ID: 17970727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.
    Jiménez W; Gal CS; Ros J; Cano C; Cejudo P; Morales-Ruiz M; Arroyo V; Pascal M; Rivera F; Maffrand JP; Rodés J
    J Pharmacol Exp Ther; 2000 Oct; 295(1):83-90. PubMed ID: 10991964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
    J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of arginine vasopressin in the nucleus raphe magnus on antinociception in the rat.
    Yang J; Chen JM; Liu WY; Song CY; Wang CH; Lin BC
    Peptides; 2006 Sep; 27(9):2224-9. PubMed ID: 16621154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.